OncoMatch/Clinical Trials/NCT06675214
Under Whole-course of Immunotherapy, Gradient Fractionated RT with CCT Versus CFRT with CCT for LANPC Who Achieved PR Post Induction Chemotherapy.
Official title: Under Whole-course of Immunotherapy, Gradient Fractionated Radiotherapy with Concurrent Chemotherapy Versus Standard Fractionated Radiotherapy with Concurrent Chemotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma Who Achieved Partial Response After Induction Chemotherapy: a Randomized, Open-label, Multicenter, Phase III Trial.
Is NCT06675214 recruiting? Yes, currently enrolling (Oct 2026). This Phase 3 trial studies multiple treatments including Full course of PD-1/PD-L1 blockades and Cisplatin-based induction chemotherapy for nasopharyngeal carcinoma.
Treatment: Full course of PD-1/PD-L1 blockades · Cisplatin-based induction chemotherapy · Concurrent Chemotherapy — This prospective trial aims to enroll patients with stage III-IVA (AJCC 8th,) locoregionally advanced nasopharyngeal carcinoma (LANPC). Under the condition of full course of PD-1/PD-L1 blockades, patients who achieved radiological partial response after 3 cycles of platinum-based chemotherapy plus PD-1/PD-L1 blockades will be randomized in a 1:1 ratio to receive gradient radiotherapy (reducing the irradiation dose of PET-CT areas without metabolic abnormalities, while maintaining adequate irradiation dose of areas with metabolic abnormalities) or standard dose radiotherapy with concurrent chemotherapy. It is expected to provide a new therapeutic option for locally advanced nasopharyngeal carcinoma at moderate risk.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Head and Neck Squamous Cell Carcinoma
Disease stage
Required: Stage III, IVA
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: platinum-based chemotherapy plus immunotherapy — induction
after 3 cycles of induction therapy of platinum-based chemotherapy plus immunotherapy
Cannot have received: chemotherapy
Exception: except diagnostic treatment
prior chemotherapy, immunotherapy, targeted therapy, or surgery (except diagnostic treatment)
Cannot have received: immunotherapy
Exception: except diagnostic treatment
prior chemotherapy, immunotherapy, targeted therapy, or surgery (except diagnostic treatment)
Cannot have received: targeted therapy
Exception: except diagnostic treatment
prior chemotherapy, immunotherapy, targeted therapy, or surgery (except diagnostic treatment)
Cannot have received: surgery
Exception: except diagnostic treatment
prior chemotherapy, immunotherapy, targeted therapy, or surgery (except diagnostic treatment)
Cannot have received: anti-PD-1 therapy
Patients who underwent anti-PD-1 /PD-L1 antibody or anti-CTLA-4 antibody (or any other antibody acting on T cell synergistic stimulation or checkpoint pathway) and anti-angiogenic drugs
Cannot have received: anti-PD-L1 therapy
Patients who underwent anti-PD-1 /PD-L1 antibody or anti-CTLA-4 antibody (or any other antibody acting on T cell synergistic stimulation or checkpoint pathway) and anti-angiogenic drugs
Cannot have received: anti-CTLA-4 therapy
Patients who underwent anti-PD-1 /PD-L1 antibody or anti-CTLA-4 antibody (or any other antibody acting on T cell synergistic stimulation or checkpoint pathway) and anti-angiogenic drugs
Cannot have received: anti-angiogenic therapy
Patients who underwent anti-PD-1 /PD-L1 antibody or anti-CTLA-4 antibody (or any other antibody acting on T cell synergistic stimulation or checkpoint pathway) and anti-angiogenic drugs
Lab requirements
Blood counts
Exact limits: see the full eligibility criteria on this page.
Kidney function
Exact limits: see the full eligibility criteria on this page.
Liver function
Exact limits: see the full eligibility criteria on this page.
Exact limits: see the full eligibility criteria on this page.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06675214 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior chemotherapy, immunotherapy, targeted therapy disqualifies patients from enrollment.
What disease stage is eligible?
Stage III or IVA is required.
Is there an age limit?
Yes. Patients must be 65 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages